Board summary
Key figures
28,320
Registered population
57.1% aged 18–64
25.6%
Aged 65+
ICB 21.9% · England 17.9%
5.1%
Ethnic minority (non-White)
1.4% Asian · England 9.6%
5.4%
In IMD quintile 1
ICB 9.2% · England 21.0%
~1,469
Core20 residents (est.)
Resident basis; registered basis ~1,541 · see page 3
4,147
Hypertension register
+6.47% in 3 yrs · England +5.60%
392
SMI register
30.9% of Lewes'
453
COPD register
Reviews +49.34% in 3 yrs
Forecast to 2030
4,791
Hypertension patients, 2030
+644 on today
62.6%
QRISK ≥20% on statins, 2030
+3.90pp over 3 yrs
6.6%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Under-80 blood pressure control trails comparators.
Control in under-80s is 56.9% (England 67.8%; Lewes 60.9%), falling 5.8% over 2023 to 2025 (England +3.2%), which may reflect unverified treatment escalation gaps.
High-risk lipid therapy below England average.
Lipid-lowering therapy covers 53.9% of QRISK ≥ 20% patients (England 63.6%) and 57.8% in CKD (England 70.3%), which could reflect unverified recall gaps.
Annual COPD and heart failure reviews.
Annual reviews reach 79.7% in COPD (+49.3% over 2023 to 2025; England 76.4%) and 82.0% in heart failure (+63.2%; England 78.5%).
Population, age and ethnicity
With 25.6% aged 65+, older adults and 14 care homes could shape needs
Foundry Healthcare Lewes PCN operates as a single practice of 28,320 registered patients. Older adults aged 65+ make up 25.6% of the list (7,255 patients), compared to Lewes (25.9%), NHS Sussex Integrated Care Board (21.9%) and England (17.9%). Working-age adults account for 57.1% (Lewes 56.4%, NHS Sussex Integrated Care Board 60.5%, England 62.7%) and children 17.3% (Lewes 17.7%, NHS Sussex Integrated Care Board 17.7%, England 19.6%). Projected list growth to 2030 is 1.6% under an unverified model.
Age profile
65+: ICB 21.9%, England 17.9%
Ethnicity
Older people · falls rows are Lewes local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Lewes LA) | 2,359 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 80.7% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 64.1% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Lewes LA) | 1,111 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Lewes LA) | 15.2 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation reaches 5.4%, exceeding Lewes by 2.5 percentage points despite low overall deprivation
The PCN average IMD decile is 6.6, less deprived than Lewes (6.2 decile), NHS Sussex Integrated Care Board (6.1 decile) and England (5.5 decile). However, 5.4% of registered patients fall into the Core20 cohort, exceeding Lewes (2.9%) by 2.5 percentage points, though below England (21.0%). This reflects an estimated 1,541 practice patients (about 1,500 residents), with 1 of 24 associated LSOAs in decile 2 and 0 in decile 1. This pocket of deprivation indicates outreach may need to focus specifically on the decile 2 neighbourhood.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
392
SMI register
1.37% recorded prevalence
137
Learning disability register
0.48% recorded prevalence
14
Care homes, 398 beds
In the PCN catchment
9.9%
Provide unpaid care
Lewes, Census 2021
Severe mental illness prevalence is 1.4% (392 patients; Lewes 1.4%, NHS Sussex Integrated Care Board 1.1%, England 1.0%), and learning disability prevalence is 0.5% (137 patients; Lewes 0.6%, NHS Sussex Integrated Care Board 0.6%, England 0.6%). Catchment data records 14 care homes with 398 beds. Local authority data shows 9.9% unpaid carers and 15 rough sleepers, which describe the wider area rather than registered patients.
Severe mental illness: physical health checks
Severe mental illness prevalence is 1.4% (392 patients). Blood pressure checks reached 83.1% (England 83.4%), while BMI recording reached 78.2% (England 82.1%) despite rising +18.5 pp over 2023 to 2025 (England +5.1 pp).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
4,147
Hypertension register
+6.47%
Register growth, 3 yrs
Lewes +5.23% · England +5.60%
−3.52pp
BP control, under 80
≤140/90 · −1.87pp aged 80+
+644
More patients by 2030
Forecast 4,791 (16.44%)
Hypertension case-finding and control
Recorded hypertension prevalence is 14.5% (4,147 patients), below Lewes (18.1%), NHS Sussex Integrated Care Board (16.3%) and England (15.2%). While 88.9% of hypertensive patients have a recent blood pressure reading (England 90.0%), treatment to target is 61.8% (England 70.3%). Under-80 blood pressure control is 56.9% (England 67.8%), falling 5.8% over 2023 to 2025 (England +3.2%), and control at age 80+ is 72.3% (England 81.2%), falling 2.5% (England +2.2%). Slower control could reflect unverified treatment escalation gaps, which a prescribing audit would test. Hypertension control trails national benchmarks across all age groups, highlighting structured reviews for uncontrolled cohorts.
Lipids and statins
Lipid-lowering therapy uptake reaches 53.9% in QRISK ≥ 20% patients (England 63.6%) and 57.8% in CKD (England 70.3%). Both trail Lewes (56.2% and 64.5%) and NHS Sussex Integrated Care Board (60.0% and 65.9%). Fewer high-risk patients receive lipid-lowering therapy than benchmarks, identifying potential statin under-treatment.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 42,125 | £2.10 | £2.42 | £1.86 | £88,462 |
| Cardiovascular (all), 2025 | 57,918 | £2.78 | £3.32 | £3.33 | £161,012 |
In 2026, the PCN prescribed 42,125 lipid-regulating drug items at £2.10 per item (England £1.86; NHS Sussex Integrated Care Board £2.42), spending £10,110 more than at England's unit cost, across 42,125 items, though unit cost does not indicate prescribing efficiency. Prescribing spend per item exceeds national rates, highlighting potential formulary review.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+31.92%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+6.16%
Asthma prevalence, PCN 3-yr % change
COPD prevalence is 1.6% (453 patients), falling 2.5% over 2023 to 2025 (England +2.6%), while 12-month COPD reviews rose +49.3% to 79.7% (England 76.4%). Asthma prevalence is 7.0% (1,921 patients), but 12-month reviews reach 56.2% (England 65.7%), leaving about 840 patients without a recorded review despite reviews rising +31.9% over 2023 to 2025 (England +4.4%). Recording second-hand smoke exposure in asthma patients aged 6-19 reached 66.8% (169 patients; England 78.8%). Prioritising routine asthma recalls and paediatric smoke recording addresses delivery shortfalls.
Cancer register and children's immunisation
Recorded cancer prevalence is 5.3% (1,505 patients; England 3.8%, Lewes 5.6%). In Q1 2025/26, 6-in-1 coverage at 12 months reached 97.9% (England 91.0%), exceeding the 95.0% target. However, MMR dose 1 coverage at 24 months was 90.6% (England 88.3%), and MMR dose 2 at age 5 was 91.1% (England 82.8%), both trailing the 95.0% target. Maintaining prompt recall is essential to achieve target herd immunity.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
58.5%
Sussex ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,360
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Sussex ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 56.6% | 53.2% | 19% | 1,668 |
| Breast | 86.1% | 85.4% | 23% | 1,400 |
| Bowel | 49.8% | 47.0% | 26% | 1,133 |
| Lung | 30.3% | 33.8% | 15% | 1,058 |
| Skin cancer | 95.3% | 87.8% | 17% | 698 |
Across NHS Sussex ICB in 2022, 58.5% of cancers with a known stage were diagnosed at stage 1 or 2 (4,799 of 8,209), exceeding England (55.3%) by 3.2 percentage points and up 5 pp since 2013, but 16.5 percentage points below the 75.0% national ambition by 2028 (a gap of about 1,360 cases). Known-stage completeness was 64.3% (England 67.0%). Within Foundry Healthcare Lewes PCN, recorded cancer prevalence is 5.3% (1,505 patients; England 3.8%), with breast screening at 77.3% (England 69.9%) and cervical screening at 69.5% (Lewes 69.8%), though cervical screening fell 1.6% over 2023 to 2025 (England -1.0%). System staging data reflects wider ICB performance.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026, University Hospitals Sussex NHS Foundation Trust achieved 65.2% on the 62-day cancer referral to treatment standard (standard 85.0%), trailing East Sussex Healthcare NHS Trust (67.0%), Maidstone and Tunbridge Wells NHS Trust (87.4%), NHS Surrey and Sussex Integrated Care Board (71.5%) and England (71.2%). The trust reached 74.0% on the 28-day faster diagnosis standard (standard 75.0%; England 79.3%). For diagnostics, 12.9% waited 6+ weeks across tests (England 23.1%), but colonoscopy reached 39.3% (East Sussex Healthcare NHS Trust 0.7%). These provider metrics describe acute system pressures, not PCN-specific delays.
| Pathways within standard (%) | Sussex | East Sussex Healthcare | Maidstone and Tunbridge Wells | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 74.01 | 84.20 | 81.78 | 79.29 | 79.32 |
| 31-day treatment (96%) | 76.79 | 98.19 | 98.35 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 65.20 | 67.04 | 87.43 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Sussex | East Sussex Healthcare | Maidstone and Tunbridge Wells | England |
|---|---|---|---|---|
| MRI | 5.62 | 6.48 | 0.92 | 21.40 |
| CT | 8.57 | 0.48 | 0.51 | 9.92 |
| Echocardiography | 0.39 | 21.94 | 2.57 | 28.48 |
| Colonoscopy | 39.35 | 0.74 | 19.80 | 30.83 |
| Gastroscopy | 20.02 | 0.31 | 24.03 | 29.02 |
| All 15 DM01 tests | 12.95 | 5.27 | 6.42 | 23.14 |
| Community services activity | East Sussex residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 100,740 | 309,615 |
| Referrals | 17,285 | 66,930 |
| Patients with a contact | 25,880 | 85,660 |
Community services (residents of East Sussex), Jun 2026 (provisional). In June 2026, East Sussex residents accounted for 100,740 community care contacts across 25,880 patients, alongside 17,285 community referrals, within NHS Surrey and Sussex Integrated Care Board's 309,615 contacts. Adults aged 65+ represented 68% of these local contacts (68,465). This experimental activity illustrates substantial community volume among older residents, though data is not available at PCN level.
Practice variation and patient experience
Practice variation and patient experience
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Foundry | 215 | 5.4 | 41.9% | 66.0% | 77.5% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Eleven of 25 measures trailed national trends, despite strong gains in clinical reviews
Across 2023 to 2025, 11 of 25 measures trailed England's change. Intermediate chronic disease control lagged: under-80 blood pressure control fell 5.8% (England +3.2%) and hypertension treated to target fell 2.7% (England +3.6%). COPD prevalence fell 2.5% (England +2.6%) and dementia fell 1.1% (Lewes fell 6.0%, England +6.0%). Conversely, annual reviews surged: heart failure reviews rose +63.2% to 82.0% (England 78.5%), COPD reviews rose +49.3% to 79.7%, and smoking cessation offers rose +25.5 pp to 98.6%. Clinical review capacity is strong, but converting reviews into effective blood pressure control remains the core priority.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
BP control, under 80
Dementia register
Hypertension treated to target
Depression register
COPD register
Heart failure reviews
COPD reviews
Asthma reviews
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Lewes | Asset | PCN | Lewes |
|---|---|---|---|---|---|
| Care homes (catchment) | 14 (398 beds) | n/a | Schools (catchment) | 33 | n/a |
| Children's centres | 1 | 2 | Places of worship | 48 | 76 |
| Libraries | 2 | 3 | Homelessness support (VCS) | 0 | no data |
| Primary schools (LA maintained) | 13 | 16 | Primary academies | 1 | 9 |
| Special schools | n/a | 2 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Hypertension and lipid control recall
Under-80 BP control is 56.9% (England 67.8%), QRISK ≥ 20% lipid therapy is 53.9% (England 63.6%), and hypertension prevalence is 14.5% (4,147 patients vs Lewes 18.1%; range +166 to +981). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 2
Asthma review and COPD audit
Asthma reviews reach 56.2% of 1,921 patients (England 65.7%; about 840 unreviewed), age 6-19 smoke recording is 66.8% (England 78.8%), and COPD is 1.6% (453 vs Lewes 2.2%; +83 to +174). Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 3
Inclusion health and Core20 checks
Learning disability prevalence is 0.5% (137 patients vs Lewes and England 0.6%; range +23 to +29), and SMI BMI recording is 78.2% of 392 patients (England 82.1%) versus 83.1% for BP. Low cost, quick to run.
Evidence base: the register is the cohort for the annual health check and LeDeR learning; people with a learning disability die on average 20 years earlier and are a Core20PLUS5 PLUS group.
Policy anchor: annual health checks for 75% of people aged 14+ on the register (Network Contract DES); Oliver McGowan mandatory training.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Learning disability register review (p2) | Learning disability: QOF prevalence | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
| Targeted Core20 neighbourhood outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Severe mental illness check reviews (p4) | SMI register with a BMI recorded in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension treatment escalation audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Childhood immunisation recall audit (p6) | MMR dose 1 coverage at 24 months | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | — | PCN |
| Option 1 · Hypertension and lipid control recall (p12) | Registered population · Hypertension register · Hypertension: QOF prevalence | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 2 · Asthma review and COPD audit (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 3 · Inclusion health and Core20 checks (p12) | Registered population · Learning disability register · Learning disability: QOF prevalence | 75% annual health checks (Network Contract DES) · Oliver McGowan · MHIS · From Harm to Hope | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
